0000950170-24-016803.txt : 20240220
0000950170-24-016803.hdr.sgml : 20240220
20240220074223
ACCESSION NUMBER: 0000950170-24-016803
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240215
FILED AS OF DATE: 20240220
DATE AS OF CHANGE: 20240220
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Francis Richard D
CENTRAL INDEX KEY: 0001673277
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-16174
FILM NUMBER: 24650748
MAIL ADDRESS:
STREET 1: IM LANGACHER 44
CITY: GREIFENSEE
STATE: V8
ZIP: 8606
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: TEVA PHARMACEUTICAL INDUSTRIES LTD
CENTRAL INDEX KEY: 0000818686
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: L3
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: TEVA PHARMACEUTICAL INDUSTRIES LIMITED
STREET 2: 124 DVORA HANEVI'A ST.
CITY: TEL AVIV
STATE: L3
ZIP: 6944020
BUSINESS PHONE: 972 (3) 914-8213
MAIL ADDRESS:
STREET 1: TEVA PHARMACEUTICAL INDUSTRIES LIMITED
STREET 2: 124 DVORA HANEVI'A ST.
CITY: TEL AVIV
STATE: L3
ZIP: 6944020
4
1
ownership.xml
4
X0508
4
2024-02-15
0000818686
TEVA PHARMACEUTICAL INDUSTRIES LTD
TEVA
0001673277
Francis Richard D
C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.
124 DVORA HANEVI'A ST.,
TEL AVIV
L3
6944020
ISRAEL
false
true
false
false
President and CEO
true
Ordinary Shares
2024-02-15
4
M
false
161655
A
161655
D
Ordinary Shares
2024-02-15
4
S
false
74530
13.1514
D
87125
D
Restricted Share Units
2024-02-15
4
M
false
161655
0
D
Ordinary Shares
161655
323311
D
The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2023.
Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.09 to $13.24, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
Restricted share units were granted on February 15, 2023, with 161,655 vesting on each of February 15, 2024 and February 15, 2025, and 161,656 vesting on February 15, 2026.
/s/ Dov Bergwerk as attorney-in-fact for Richard D. Francis
2024-02-20